Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Updated: 10/6/2022

Antiarrhythmics

0%
Topic
Review Topic
0
0
N/A
N/A
Questions
17
0
0
0%
0%
Evidence
21
0
0
0%
0%
Videos / Pods
1
Topic
Images
https://upload.medbullets.com/topic/108097/images/ventricular_myocyte_action_potential.svg.jpg
https://upload.medbullets.com/topic/108097/images/cardiac drugs.jpg
  • Snapshot
    • A 65-year-old man with atrial fibrillation presents to his primary care physician for a rash. He reports that he recently switched antiarrhythmic medications as instructed by his cardiologist. He reports to having discoloration of his skin and a burning sensation after sun exposure. On physical exam, there are blue and gray discolorations of his skin. An eye exam also reveals yellow-brown granules in the cornea. He was discontinued from the new anti-arrhythmic medication. (Amiodarone photosensitivity)
  • Introduction
    • Anti-arrhythmic medications are divided into 4 classes
      • Class I drugs are Na+ channel blockers
      • Class II drugs are β-blockers
      • Class III drugs are K+ channel blockers
      • Class IV drugs are Ca2+ channel blockers
      • Anti-arrhythmics
      • Class
      • Drugs
      • Mechanism
      • Class IANa+ channel blockers
      • DoubleQuarterPounder
        • Disopyramide
        • Quinidine
        • Procainamide
      • ↑ Action potential (AP)↑ Effective refractory period (ERP)↑ QT interval
      • Class IBNa+ channel blockers
      • Lettuce and Mayo
        • Lidocaine
        • Mexiletine
      • ↓ AP
      • ↓ ERP
        • affects ischemic or depolarized tissue
          • hence, great for post-myocardial infarction arrhythmias
      • Class ICNa+ channel blockers
      • Fries Please
        • Flecainide
        • Propafenone
      • ERP in atrioventricular node but not in ventricular tissue
      • Class II β-blockers
      • Drug name - lol
      • Selective β-blockers
        • metoprolol, esmolol, propranolol, atenolol, and timolol
        • esmolol is the most short-acting
      • Nonselective α- and β-blockers
        • carvedilol
        • labetalol
      • ↓ Sinoatrial and atrioventricular nodal activity
        • ↓ cAMP and ↓ Ca2+ currents
        • ↓ slope of phase 4
      • ↑ PR interval
      • Class III K+channel blockers
        • Amiodarone
        • Ibutilide
        • Dofetilide 
        • Sotalol
      • ↑ AP
      • ↑ ERP
      • ↑ QT interval
      • Class IV Ca2+channel blockers
      • Class IDrugs
        • Verapamil
        • Diltiazem
      • ↑ ERP
      • ↑ PR interval
      • ↓ Conduction velocity
  • Class I - Na+ Channel Blockers
    • These drugs slow down conduction and ↓ slope of phase 0 depolarization
    • Class IA (disopyramide, quinidine, and procainamide)
      • clinical use
        • atrial and ventricular arrhythmias
          • re-entrant and ectopic supraventricular tachycardias (SVTs) and ventricular tachycardias (VTs)
      • toxicity
        • thrombocytopenia
        • torsades de pointes
          • from ↑ QT interval
        • heart failure (disopyramide)
        • headache (quinidine)
        • tinnitus (quinidine)
        • reversible systemic lupus erythematosus-like syndrome (procainamide)
    • Class IB (lidocaine and mexiletine)
      • clinical use
        • post-myocardial infarction and other ventricular arrhythmias
        • digitalis-induced arrhythmias
      • toxicity
        • cardiovascular depression
        • central nervous system effects
    • Class IC (flecainide and propafenone)
      • clinical use
        • SVTs, including atrial fibrillation
      • toxicity
        • proarrhythmic
        • contraindicated in structural and ischemic heart disease, especially post-myocardial infarction
  • Class II - β-Blockers
    • Clinical use
      • SVTs, including atrial fibrillation and atrial flutter
    • Toxicity
      • impotence
      • exacerbation of lung disease (chronic obstructive pulmonary disease and asthma)
      • cardiovascular effects
        • bradycardia
        • atrioventricular block
        • heart failure
      • central nervous system effects
        • sedation
        • sleep disturbance
      • dyslipidemia (metoprolol)
      • exacerbate Prinzmetal angina (propranolol)
    • Treatment for an overdose of β-blockers
      • saline
      • atropine
      • glucagon
  • Class III - K+ Channel Blockers
    • Clinical use
      • atrial fibrillation
      • atrial flutter
      • VT
        • especially amiodarone and sotalol
    • Toxicity
      • torsades de pointes (sotalol and ibutilide)
      • excessive β-blockade (sotalol)
      • amiodarone
        • no risk of torsades de pointes
        • check pulmonary function tests (PFTs), liver function tests (LFTs), and thyroid function tests (TFTs)
          • pulmonary fibrosis
          • hepatotoxicity
          • thyrotoxicity
        • blue/gray skin deposits and photodermatitis
        • corneal deposits
        • neurologic effects
        • gastrointestinal effects
        • cardiovascular depression
          • bradycardia
          • heart block
          • heart failure
  • Class IV - Ca2+ Channel Blockers
    • Clinical use
      • atrial fibrillation
      • prevention of SVT
    • Toxicity
      • constipation
      • flushing
      • edema
      • cardiovascular depression
        • heart failure
        • atrioventricular block
        • sinus node depression
  • Other Anti-Arrhythmics
    • Adenosine
      • mechanism
        • ↑ K+ out of cells causes hyperpolarization of the cell and decreased atrioventricular node conduction
        • very short-acting (approximately 15 seconds)
      • clinical use
        • diagnosing and/or terminating SVT
      • toxicity
        • flushing
        • hypotension
        • chest pain
        • sense of impending doom
        • bronchospasm
    • Mg2+
      • clinical use
        • torsades de pointes
        • digoxin toxicity
      • toxicity
        • lethargy
        • bradycardia
Flashcards (0)
Cards
1 of 0
Questions (17)
Question locked
Sorry, this question is for
PEAK Premium Subscribers only
Upgrade to PEAK
Question locked
Sorry, this question is for
PEAK Premium Subscribers only
Upgrade to PEAK
Question locked
Sorry, this question is for
PEAK Premium Subscribers only
Upgrade to PEAK
Question locked
Sorry, this question is for
PEAK Premium Subscribers only
Upgrade to PEAK
Question locked
Sorry, this question is for
PEAK Premium Subscribers only
Upgrade to PEAK
Question locked
Sorry, this question is for
PEAK Premium Subscribers only
Upgrade to PEAK
Question locked
Sorry, this question is for
PEAK Premium Subscribers only
Upgrade to PEAK

(M1.CV.15.75) A 65-year-old female with a history of HTN, type 2 diabetes, and asthma presents to the emergency department with severe nausea, sweating, and shortness of breath. The emergency room physician obtains an EKG which is demonstrated in Figure A. She immediately receives treatment for her condition and is subsequently admitted to the cardiac intensive care unit (CICU). In the CICU, the patient has episodes of recurrent sustained ventricular tachycardia. The hospital is in short supply of amiodarone, so the attending physician starts lidocaine IV to prevent the development of an arrhythmia. Which of the following toxicities is associated with this medication?

QID: 106835
FIGURES:

Central nervous system effects

69%

(207/300)

Cinchonism

8%

(23/300)

Torsades de pointes

13%

(39/300)

Exacerbation of asthma

3%

(9/300)

Flushing

6%

(18/300)

M 1 E

Select Answer to see Preferred Response

(M1.CV.15.75) A 50-year-old male is being treated for ventricular arrhythmias and presents to the cardiologist, as he is concerned about the recent skin changes he has seen in his face (Figure A). Which of the following phases of the action potential is affected by this patient's medication (See Figure B)?

QID: 106840
FIGURES:

0

14%

(26/188)

1

4%

(8/188)

2

11%

(20/188)

3

68%

(127/188)

4

3%

(5/188)

M 1 C

Select Answer to see Preferred Response

(M1.CV.13.99) A 50-year-old male is seen in your clinic. Physical examination reveals a resting heart rate of 120. You perform an ECG (the reading from the V5 lead is shown in Figure A). After reviewing the ECG, you decide to start the man on a medication that primarily reduces the rate of depolarization during phase 0 and the latter part of phase 4 in cardiac slow-response tissue. What is the medication?

QID: 100615
FIGURES:

Amlodipine

10%

(35/361)

Ezetimibe

4%

(14/361)

Adenosine

19%

(69/361)

Nifedipine

6%

(21/361)

Verapamil

61%

(220/361)

M 1 E

Select Answer to see Preferred Response

(M1.CV.13.29) A 62-year-old man presents to the emergency department complaining of chest tightness. An electrocardiogram reveals ST segment elevation in the infero-lateral leads. He is treated for an acute myocardial infarction. His hospitalization is complicated by ectopy and several runs of non-sustained ventricular tachycardia. In an effort to reduce the risk of further arrhythmia in the post-myocardial infarction period, he is started on a Class 1 antiarrhythmic medication with very low affinity for its target channel. Which of the following images best represents the effect of the likely medication on the patient's action potential?

QID: 100545
FIGURES:

Figure A

14%

(23/164)

Figure B

57%

(94/164)

Figure C

13%

(21/164)

Figure D

14%

(23/164)

No effect

1%

(1/164)

M 1 D

Select Answer to see Preferred Response

Question locked
Sorry, this question is for
PEAK Premium Subscribers only
Upgrade to PEAK

(M1.CV.13.9) A 63-year-old man with a history of hypertension and atrial fibrillation is brought into the emergency room and found to have a ventricular tachyarrhythmia. Ibutilide is discontinued and the patient is switched to another drug that also prolongs the QT interval but is associated with a decreased risk of torsades de pointes. Which drug was most likely administered in this patient?

QID: 100525

Sotalol

10%

(18/175)

Digoxin

6%

(11/175)

Esmolol

2%

(3/175)

Amiodarone

75%

(131/175)

Quinidine

7%

(12/175)

M 1 D

Select Answer to see Preferred Response

(M1.CV.12.16) A 57-year-old woman with a history of diabetes and hypertension accidentally overdoses on antiarrhythmic medication. Upon arrival in the ER, she is administered a drug to counteract the effects of the overdose. Which of the following matches an antiarrhythmic with its correct treatment in overdose?

QID: 100532

Quinidine and insulin

3%

(11/346)

Encainide and epinephrine

8%

(29/346)

Propafenone and glucose

2%

(8/346)

Metoprolol and glucagon

69%

(238/346)

Sotalol and norepinephrine

15%

(52/346)

M 3 E

Select Answer to see Preferred Response

(M1.CV.12.110) A 58-year-old Caucasian male is being treated for atrial fibrillation and angina complains of dyspnea on exertion. On exam, his heart rate 104-115/min and irregularly irregular at rest. He has no chest pain. You believe his rate control for atrial fibrillation is suboptimal and the likely cause of his dyspnea. You are considering adding verapamil to his current metoprolol for additional rate control of his atrial fibrillation. Which of the following side effects should you be most concerned about with this additional medication?

QID: 100626

Diarrhea

9%

(12/132)

Shortening of action potential length at the AV node

17%

(23/132)

Tachycardia

9%

(12/132)

Hypotension

55%

(72/132)

Torsades de pointes

10%

(13/132)

M 1 E

Select Answer to see Preferred Response

Question locked
Sorry, this question is for
PEAK Premium Subscribers only
Upgrade to PEAK

(M1.CV.12.106) A 57-year-old Caucasian male presents to your office with heart palpitations and shortness of breath. On exam, he is tachycardic and his rhythm is irregularly irregular. He fails standard pharmacologic therapy and you refer to cardiology, where he is started on an antiarrhythmic medication. The action of this agent results in a longer action potential duration, an increased effective refractory period, and a longer QT interval. Which drug has been prescribed?

QID: 100622

Flecanide

6%

(9/149)

Propafenone

2%

(3/149)

Mexiletine

5%

(7/149)

Diltiazem

9%

(14/149)

Sotalol

76%

(113/149)

M 1 E

Select Answer to see Preferred Response

Evidence (21)
VIDEOS & PODCASTS (2)
EXPERT COMMENTS (53)
Private Note